e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer
Maysa Alhawmdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson, Mojgan Najafzadeh
Source:
ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Maysa Alhawmdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson, Mojgan Najafzadeh. Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer. ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Are biphosphonates efficient in the adjuvant treatment of lung cancer?
Source: Eur Respir J 2006; 28: Suppl. 50, 754s
Year: 2006
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Source: Eur Respir J 2014; 44: 1011-1022
Year: 2014
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
Pulmonary surfactant as drug delivery system to target lung epithelium: new approach for the treatment of epithelial injury after bleomycin challenge
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Targeted therapies for lung cancer: how did the game begin?
Source: Breathe 2016; 12: 177-179
Year: 2016
Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future?
Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem
Year: 2005
Precision medicine for lung cancer: new targeted treatments
Source: International Congress 2017 – Precision medicine approaches in lung cancer
Year: 2017
30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Source: ERJ Open Res, 4 (4) 00030-2018; 10.1183/23120541.00030-2018
Year: 2018
Innovative local therapies in lung cancer
Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy
Year: 2018
Inhaled solid lipid nanoparticles as a new tool for drug delivery in the lung
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Aerosol delivery of chemotherapy in an orthotopic model of lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Lung cancer: does age affect treatment strategy?
Source: Eur Respir Mon; 2009: 43:306–326
Year: 2009
Advances in target therapy in lung cancer
Source: Eur Respir Rev 2015; 24: 23-29
Year: 2015
Advances in target therapy for lung cancer
Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I
Year: 2014
Checkpointinhibition in lung cancer – already standard of care in any line of therapy?
Source: International Congress 2017 – Lung cancer immunotherapy
Year: 2017
Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future?
Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments
Year: 2019
Nurse led lung cancer diagnostic/supportive follow up clinic;a different approach to optimise lung cancer pathway
Source: International Congress 2018 – The many facets of respiratory nursing
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept